Literature DB >> 11920637

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

Takashi Taga1, Atsushi Suzuki, Ignacio Gonzalez-Gomez, Floyd H Gilles, Monique Stins, Hiroyuki Shimada, Lora Barsky, Kenneth I Weinberg, Walter E Laug.   

Abstract

Orthotopic brain tumor growth is inhibited in athymic mice by the daily systemic administration of the alpha v-integrin antagonist EMD 121974. This compound, a cyclic RGD-penta-peptide, is a potent inhibitor of angiogenesis, which induces apoptosis of growing endothelial cells through inhibition of their alpha v-integrin interaction with the matrix proteins vitronectin and tenascin. Here we show that EMD 121974 also induces apoptosis in the alpha v-integrin-expressing tumor cell lines U87 MG and DAOY by detaching them from vitronectin and tenascin, matrix proteins known to be essential for brain tumor growth and invasion. These matrix proteins are shown to be produced by the brain tumor cells in vitro and in vivo. Furthermore, only tumor cells expressing alpha v-integrins responded to the treatment with EMD 121974, after xenotransplantation into the forebrain of nude mice, supporting the importance of tumor cell-matrix interactions in tumor cell survival in the brain. Thus, the alpha v-antagonist EMD 121974 suppresses brain tumor growth through induction of apoptosis in both brain capillary and brain tumor cells by preventing their interaction with the matrix proteins vitronectin and tenascin. The dual action of this peptide explains its potent growth suppression of orthotopically transplanted brain tumors. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920637     DOI: 10.1002/ijc.10265

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

Review 1.  Functional peptide sequences derived from extracellular matrix glycoproteins and their receptors: strategies to improve neuronal regeneration.

Authors:  Sally Meiners; Mary Lynn T Mercado
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

Review 2.  [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].

Authors:  G Tabatabai; R Stupp
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Authors:  Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

4.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

5.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

Review 6.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

7.  Inhibition of lung tumor colonization and cell migration with the disintegrin crotatroxin 2 isolated from the venom of Crotalus atrox.

Authors:  Jacob A Galán; Elda E Sánchez; Alexis Rodríguez-Acosta; Julio G Soto; Sajid Bashir; Mary Ann McLane; Carrie Paquette-Straub; John C Pérez
Journal:  Toxicon       Date:  2008-02-19       Impact factor: 3.033

8.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

9.  MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.

Authors:  Xiaoyuan Chen; Ryan Park; Yingping Hou; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; Michel Tohme; James R Bading; Walter E Laug; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.